FDA pathways, SaMD, adaptive AI oversight, regulatory terminology, and postmarket monitoring for clinical AI.
FDA and regulatory coverage for clinical AI must be precise. A tool may be cleared, approved, authorized, registered, or marketed under another pathway, and those labels are not interchangeable. This section is designed to help clinicians, buyers, and vendors understand those differences without relying on vague shorthand.
Regulatory status also changes over time. Coverage here focuses on the intended use of the software, the pathway used, what that status does and does not mean, and how release criteria, change control, inspection readiness, and ongoing monitoring affect adoption decisions.
AI product release criteria help health systems and vendors decide whether a clinical AI tool is ready for pilot, go-live, expansion, or re-release after a model or workflow change.
FDA inspection readiness for AI-enabled clinical software is mainly quality-system readiness: intended use, design controls, software validation, risk management, change control, complaints, CAPA, labeling, and lifecycle records.
Clinical AI governance is usually discussed at the model, vendor, and workflow levels. But hospitals also need to govern the infrastructure below the application layer: data locality, uptime, access, logs, monitoring, recovery, and system change.
AI drug discovery tools are moving from early target and compound work into clinical research, real-world data, trial design, and regulatory evidence. The useful question is how each AI output becomes credible enough to support a drug development decision.
FDA clearance is an important signal for clinical AI, but it is not the whole evaluation. Research teams and hospital buyers need to read clearance, intended use, change control, local validation, and post-deployment monitoring together.
AI symptom assessment and clinical diagnosis are not the same workflow. Symptom tools may support triage or intake, while diagnosis requires clinician evaluation and accountability.
FDA-cleared AI diagnostic software should be evaluated by intended use, clearance pathway, clinical evidence, transparency, updates, workflow fit, and monitoring.
Evaluate an AI diagnostic platform by intended use, evidence, regulatory status, workflow fit, privacy, integration, monitoring, governance, and commercial risk.
Medical AI search engines can help users discover tools and evidence, but clinical evaluation still requires source quality, intended use, and governance review.
AI-assisted diagnosis uses algorithmic output to support clinical reasoning, detection, triage, and diagnostic review. It should strengthen clinician judgment, not replace it.
A medical AI platform is a clinical or operational software layer that supports AI tools across workflows, data sources, governance, and deployment.
A useful medical AI website helps clinicians and buyers compare use cases, evidence, regulatory status, workflow fit, vendors, and safety questions.
A clinical AI governance framework gives hospitals a way to review, deploy, monitor, and retire AI tools with clear accountability. The goal is not bureaucracy for its own sake, but safer decisions around risk, evidence, privacy, workflow, vendor management, and ongoing oversight.
Use this clinical AI procurement scorecard to flag review gaps before a hospital signs a vendor contract, starts a pilot, or expands a clinical AI tool.
Clinical artificial intelligence covers AI systems used in diagnosis, decision support, imaging, documentation, and treatment planning. The real question is not whether a tool uses AI, but whether it solves a defined clinical problem with credible evidence, safe workflow fit, and responsible governance.
Hospitals should not evaluate clinical AI vendors like ordinary software purchases. The right process starts with a defined clinical problem, then moves through evidence, regulatory status, workflow fit, privacy, governance, contracting, and post-deployment monitoring.
Regulatory review does not end with a status label.
Clinical AI teams need:
For regulated device software, that documentation supports quality-system and inspection readiness.
For non-device AI tools, the same discipline helps local governance teams decide whether the tool is ready for clinical use.
Regulatory content should always identify source date, last reviewed date, primary sources, and the exact regulatory term being used. Regulatory status may change, so every article in this section should be revisited on a regular review cycle.